drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A bispecific T‑cell engager antibody (DLL3×CD3) administered intravenously that binds DLL3 on tumor cells and CD3 on T cells to redirect/activate cytotoxic T cells and induce tumor lysis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Intravenous bispecific antibody that binds DLL3 on tumor cells and CD3 on T cells, forming a cytolytic synapse to redirect and activate T cells independent of MHC, leading to perforin/granzyme-mediated lysis of DLL3-expressing neuroendocrine tumor cells.
drug_name
Obrixtamig (BI 764532)
nct_id_drug_ref
NCT05879978